

**Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease**

Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, Davis SM, Lebowitz BD, Rabins P, Hsiao JK, Lieberman JA, Schneider LS.

Archives of general psychiatry

2007; 64(11):1259-1268

**ARTICLE IDENTIFIERS**

DOI: 10.1001/archpsyc.64.11.1259

PMID: 17984395

PMCID: not available

**JOURNAL IDENTIFIERS**

LCCN: not available

pISSN: 0003-990X

eISSN: 1538-3636

OCLC ID: not available

CONS ID: not available

US National Library of Medicine ID: not available

This article was identified from a query of the SafetyLit database.